ArticleInfection and drug resistance2025
Poor Glycemic Control in Carbapenem-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- <p>Molecular medicine reports · 2026Review
- The oral cavity as a reservoir for resistance- and hypervirulence-associated genes ofFrontiers in microbiology · 2026Article
- Clinical risk factors and genomic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the relationship between glycemic control and epidemiological characteristics of patients infected with carbapenem-resistant Patients and Methods: Clinical cases of 218 patients infected with CRKP were collected from a large tertiary public hospital in Anhui Province. We analyzed whether the glycemic control impacts the clinical and laboratory manifestations of infected patients. Logistic regression identified mortality risk factors. Antibiotic sensitivity, capsular serotypes, and virulence genes were tested of the strains. Three clinically isolated CRKP strains were used to investigate the effect of glucose on bacterial capsule synthesis and the impact on bacterial resistance to polymyxin and serum killing. Results: Patients with poor glycemic control experienced more severe infections and had a higher likelihood of chronic kidney disease (CKD) and acute renal insufficiency compared to those with good glycemic control. They also exhibited an increased mortality rate. Logistic regression analysis identified age, glycosylated hemoglobin (HbA Conclusion: A persistent hyperglycemic environment resulting from poor glycemic control may stimulate the synthesis of CRKP capsules, which could enhance the resistance of CRKP to polymyxin and serum killing, thereby further increasing the risk of patient mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.